

MCQOPTIONS
Saved Bookmarks
This section includes 10 Mcqs, each offering curated multiple-choice questions to sharpen your Tissue Engineering knowledge and support exam preparation. Choose a topic below to get started.
1. |
Which of the following Tissue Engineering products has been approved by the European Medicines Agency (EMA) as an Advanced Therapy medicinal product (Drug)? |
A. | ChondroCelect<sup> </sup> |
B. | CarticelTM |
C. | Provenge<sup> </sup> |
D. | Laviv<sup> </sup> |
Answer» B. CarticelTM | |
2. |
Name one 361 HCT/P which cannot be imported. |
A. | Cartilage |
B. | Bone |
C. | Infected Peripheral Blood Stem Cells |
D. | Cornea |
Answer» B. Bone | |
3. |
_____________ need to register with FDA under Title 21 of Code of Federal Regulations (CFR). |
A. | Laboratories doing speciation of microorganisms detected in HCT/P cultures |
B. | Companies collecting Blood samples from donors |
C. | School laboratories |
D. | Hospitals storing HTC/Ps |
Answer» B. Companies collecting Blood samples from donors | |
4. |
Umbilical cord blood stem cells are an example of 361 HCT/Ps that meet the criteria in Title 21 of CFR part 1271. |
A. | True |
B. | False |
Answer» B. False | |
5. |
Which Act governs the manufacture of HCT/Ps? |
A. | Public Health Service Act |
B. | Food, Drug, and Cosmetic Act |
C. | Food Adulteration Act |
D. | Meat Food Products Order |
Answer» B. Food, Drug, and Cosmetic Act | |
6. |
Title ______________ constitutes of a comprehensive regulatory Framework for the producers of human cells, tissues, and cellular and tissue-based products (HCT/Ps). |
A. | 21 CFR Part 1271 |
B. | 21 CFR Part 1308 |
C. | 21 CFR Part 110 |
D. | 21 CFR Part 111 |
Answer» B. 21 CFR Part 1308 | |
7. |
Which is the Competent Authority for tissues and cells in the United Kingdom? |
A. | Human Tissue Authority |
B. | Health and Youth Care Inspectorate |
C. | Medical Products Agency |
D. | Slovenija-transplant |
Answer» B. Health and Youth Care Inspectorate | |
8. |
Prosthetic devices are capable of restoring normal function, and the number of organ donors is always way less than required. |
A. | True |
B. | False |
Answer» C. | |
9. |
The driving force behind the conceptualization of in vivo culturing of tissues was the limited number of donors available and graft-rejection by the immune system. |
A. | True |
B. | False |
Answer» C. | |
10. |
What is the Goal of Tissue Engineering? |
A. | Providing biological substitutes to maintain and improve the function of damaged tissues |
B. | Cure or slow down a genetic disease by repairing the damaged gene responsible for the disease |
C. | Restore structure and function of damaged tissues and organs |
D. | Identifying basic genetic and molecular defects causing a disease, and developing <i>molecular</i> interventions to treat the same |
Answer» B. Cure or slow down a genetic disease by repairing the damaged gene responsible for the disease | |